Luca Cantini

7PUBLICATIONS
18CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Oct 14, 2022
The Landscape of ALK-Rearranged Non-Small Cell Lung Cancer: A Comprehensive Review of Clinicopathologic, Genomic Characteristics, and Therapeutic Perspectives.

Valeria Cognigni, Federica Pecci, Alessio Lupi

|Sep 01, 2022
Tumor burden as possible biomarker of outcome in advanced NSCLC patients treated with immunotherapy: a single center, retrospective, real-world analysis.

Edoardo Lenci, Giulia Marcantognini, Valeria Cognigni

|Sep 01, 2022
Old but gold: the role of drug combinations in improving response to immune check-point inhibitors in thoracic malignancies beyond NSCLC.

Luca Cantini, Federica Pecci, Filippo Merloni

|Sep 01, 2022
Management of lung cancer patients during COVID-19 pandemic: dos, don'ts and don't knows.

Mariangela Torniai, Veronica Agostinelli, Luca Cantini

|Sep 30, 2021
Retrospective Cohort Study of Caveolin-1 Expression as Prognostic Factor in Unresectable Locally Advanced or Metastatic Pancreatic Cancer Patients.

Alessandro Bittoni, Riccardo Giampieri, Federica Pecci

|Apr 30, 2021
Seroprevalence of SARS-CoV-2-Specific Antibodies in Cancer Patients Undergoing Active Systemic Treatment: A Single-Center Experience from the Marche Region, Italy.

Luca Cantini, Lucia Bastianelli, Alessio Lupi

Pageof 2

Frequent Collaborators

6 joint publications

Rossana Berardi

3 joint publications

Giada Pinterpe

2 joint publications

Edoardo Lenci

2 joint publications

Alessio Lupi